Markets US

Eli Lilly CEO Dave Ricks revealed that one-third of new GLP-1 pill patients are using the company's Foundayo, as Lilly accelerates production of the obesity drug. The CEO made the remarks during the groundbreaking of a $6.5 billion Houston manufacturing facility, set to operate by 2030, amid rising demand driven by Medicare's expanded obesity drug coverage. The data highlights Lilly's growing market share in the GLP-1 space, where it now competes directly with Novo Nordisk.

Lilly's CEO, Dave Ricks, stated during a CNBC interview that Foundayo has captured one-third of new GLP-1 pill prescriptions in the U.S., with the drug generating $98 million in sales during the second quarter of 2026. The company reported that 700,000 U.S. seniors began using GLP-1 drugs following Medicare coverage expansion in July 2025, with 70% of those patients on Lilly's medications. The Houston facility, a key part of Lilly's $50 billion manufacturing expansion since 2020, will produce Foundayo and active ingredients for other small-molecule drugs across cardiometabolic, oncology, and neuroscience therapies.

The production scaling and market share growth underscore Lilly's strategic push to challenge Novo Nordisk's early lead in the GLP-1 pill market. With Foundayo's U.S. launch in April 2026 and Medicare's expanded access to obesity treatments, Lilly aims to solidify its position in the $15 billion obesity treatment sector. The Houston site, expected to be operational by 2030, reflects Lilly's commitment to reshoring manufacturing and competing with Novo's global supply chain.

Stakeholders including investors, patients, and competitors are impacted by the developments. Lilly's production expansion could bolster stock valuation and investor confidence, while Medicare coverage improves access to GLP-1 drugs like Foundayo and Zepbound. Competitors like Novo Nordisk face pressure as Lilly's market share grows, though Novo retains a first-mover advantage in the pill space. Regulators are also watching as policy-driven demand for obesity treatments continues to rise.

Lilly's Houston manufacturing facility is expected to be operational by 2030, with Foundayo sales data for Q2 2026 already reported at $98 million. The company's production ramp-up will support future product launches and meet growing demand for obesity and diabetes treatments.

Lilly's strategy to expand Foundayo's market share through production scaling and Medicare-driven demand positions it to challenge Novo Nordisk's dominance. The success of this approach will hinge on maintaining supply chain efficiency and retaining leadership in the obesity treatment sector amid increasing competition.

Topics: Healthcare Innovation, Obesity Treatment, Drug Manufacturing, Pharmaceutical Industry, Medicare Coverage, Market Share Growth, Biotechnology, Pharmaceutical Companies, Drug Development, Health Policy

#EliLilly #Foundayo #GLP1Drugs #MedicareCoverage #ObesityTreatment #Pharmaceuticals #DrugMarket #HealthInnovation #HealthPolicy #Biotechnology

Source: CNBC